It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare manifestation of Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2) infection that can result in increased morbidity and mortality. Mounting evidence describes sex disparities in the clinical outcomes of coronavirus disease 2019 (COVID-19). However, there is a lack of information on sex-specific differences in immune responses in MIS-C. This study is an observational and cross-sectional study and we wanted to examine immune parameters such as cytokines, chemokines, acute phase proteins (APPs), growth factors, microbial translocation markers (MTMs), complement components and matrix metalloproteinases (MMPs) in MIS-C children, based on sex. Male children were associated with heightened levels of pro-inflammatory cytokines—IFNγ, IL-2, TNFα, IL-1α, IL-1β, IL-6, IL-12, G-CSF and GM-CSF, chemokines-CCL2, CCL11, CXCL1, CXCL8 and CXCL10, acute phase proteins-α-2M, CRP, growth factors VEGF and TGFα, microbial translocation markers- iFABP, LBP, EndoCAb, complement components—C1q, MBL and C3 and matrix metalloproteinases MMP-8 and MMP-9 compared to female children with MIS-C. These results indicate that the heightened immune response in males is a characteristic feature of MIS-C. These findings might explain the differential disease pathogenesis in males compared to females with MIS-C and facilitate a deeper understanding of this disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 National Institutes of Health-National Institute for Research in Tuberculosis – International Center for Excellence in Research, Chennai, India (GRID:grid.417330.2) (ISNI:0000 0004 1767 6138)
2 National Institute for Research in Tuberculosis, Chennai, India (GRID:grid.417330.2) (ISNI:0000 0004 1767 6138)
3 Institute of Child Health and Hospital for Children, Chennai, India (GRID:grid.416256.2) (ISNI:0000 0001 0669 1613)
4 Dr. Mehta’s Children’s Hospital, Chennai, India (GRID:grid.459764.d) (ISNI:0000 0004 1803 4559)
5 Rainbow Children’s Hospital, Chennai, India (GRID:grid.464660.6) (ISNI:0000 0004 1801 0717)
6 Kanchi Kamakoti CHILDS Trust Hospital, Chennai, India (GRID:grid.412931.c) (ISNI:0000 0004 1767 8213)
7 National Institutes of Health-National Institute for Research in Tuberculosis – International Center for Excellence in Research, Chennai, India (GRID:grid.417330.2) (ISNI:0000 0004 1767 6138); National Institutes of Health, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)